Full Press Release Details
Mereo BioPharma Group plc
( Mereo or the Company or the Group )
Result of General Meeting
and Redwood City, Calif., September 28, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), Mereo or the Company , a clinical-stage biopharmaceutical company focused on oncology and rare
diseases, announces that all five resolutions (the Resolutions ) proposed at the Company s General Meeting ( General Meeting ), held earlier today, were duly passed. The Board is pleased that all the resolutions
received strong support from shareholders. Full details of the resolutions can be viewed in the Notice of General Meeting on the Company s website at www.mereobiopharma.com
The results of the proxy voting in advance of the General Meeting are shown below. On the record date there were 338,713,962 ordinary shares of 0.003
each in issue, each carrying one vote per share.
| Resolution | Votes For | Votes at Chairman s Discretion | Votes Against | Votes Withheld | Total Votes Cast | Result | ||||||
| 1 | 129,413,324 | 0 | 9,258,138 | 17,565 | 138,689,027 | Passed | ||||||
| 2 | 138,317,100 | 0 | 178,850 | 193,077 | 138,689,027 | Passed | ||||||
| 3 | 138,558,837 | 0 | 92,945 | 37,245 | 138,689,027 | Passed | ||||||
| 4 | 125,187,297 | 0 | 13,290,680 | 211,050 | 138,689,027 | Passed | ||||||
| 5 | 124,695,799 | 0 | 13,216,200 | 777,028 | 138,689,027 | Passed |
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes
for oncology and rare diseases. Mereo s lead oncology product candidate, etigilimab (Anti-TIGIT), has completed a Phase 1a dose escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b study in
combination with nivolumab in select tumor types. Mereo s rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta (OI), as well as alvelestat, which is
being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency (AATD) and in a
Phase 1b/2 clinical trial in COVID-19 respiratory disease.
Mereo BioPharma Contacts:
| Mereo | +44 (0)333 023 7300 | |
| Denise Scots-Knight, Chief Executive Officer | ||
| N+1 Singer (Nominated Adviser and Broker to Mereo) | +44 (0)20 7496 3081 | |
| Phil Davies | ||
| Will Goode |
| Burns McClellan (US Investor Relations Adviser to Mereo) | + 01 212 213 0006 | |
| Lisa Burns | ||
| Steve Klass | ||
| FTI Consulting (UK Public Relations Adviser to Mereo) | +44 (0)20 3727 1000 | |
| Simon Conway | ||
| Ciara Martin | ||
| Investors | investors@mereobiopharma.com |